SecBot SecBot
Insider Cluster (3 insiders) ·Filed Aug 14, 2026

SEPN

Septerna, Inc.
BEARISH
Impact 7/10
Horizondays Processed3mo ago
Insider cluster: 3 insiders, $40.2M total
Actionable Insight ▼ Bearish

The magnitude of insider selling by two major holders (RA Capital and Third Rock) is unusually large relative to market cap and signals potential lack of confidence in near-term catalysts. Monitor for further insider sales or a potential secondary offering. The narrowed loss and cash runway are positive but do not offset the selling pressure from informed holders.

DirectionBearish
Confidencehigh
Horizondays

Drugs in focus

SEPN drug pipeline →

SEP-479

● Neutral Named in this insider cluster
Impact
Phase
Phase 1
Time to market
If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$44.20
T+0 close · Aug 14, 2026 · via day close
Latest settled
+18.42%
T+60 · $52.34
Vs SPY
+21.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $44.20entry
  2. T+1 · 3mo ago −0.91%α −0.23% · $43.80
  3. T+5 · 3mo ago −8.33%α −7.14% · $40.52
  4. T+20 · 2mo ago −12.08%α −10.10% · $38.86
  5. T+60 · 6d ago +18.42%α +21.36% · $52.34
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna insiders sold $40.2M in stock over a 7-day window, led by a $31.7M open-market sale by director/10% owner RA Capital Management at $42.50, and a $7.4M sale by Third Rock Ventures. President/COO Bhatt exercised options and sold $1.1M at $44.00. The sales follow Q2 earnings (net loss narrowed to $13.0M, $516.5M cash runway into 2029) and a strategic pipeline shift for SEP-631. The total sales represent ~12.4% of market cap, a highly material cluster dominated by two large holders reducing positions, which is bearish despite the cash runway and narrowed loss.

Key Financial Metrics

Direction
selling
Total Value
$40.2M
Insiders
3

Key Facts

  • RA Capital Management sold 746,500 shares at $42.50 for $31.73M
  • Third Rock Ventures sold 147,059 shares at $50.27 for $7.39M
  • President/COO Bhatt sold 25,000 shares at $44.00 for $1.10M after exercising options
  • Total insider sales of $40.2M represent ~12.4% of Septerna's ~$324M market cap
  • Q2 2026 net loss of $13.0M narrowed from $24.8M YoY; cash of $516.5M funds operations into 2029
  • SEP-631 shifted from Phase 2b CSU study to signal-finding studies in mast cell diseases

Financial Impact

Insider sales of $40.2M represent ~12.4% of market cap; two large holders (RA Capital and Third Rock) sold significant positions

market capinsider ownershipfloat

Risk Factors

  • Further insider selling or secondary offering from remaining large holders
  • SEP-479 Phase 1 data not expected until Q1 2027, limiting near-term catalysts
  • Strategic pivot for SEP-631 introduces pipeline uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-SEPN-1786775263080

Track record

24 reports on SEPN

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  2. Nov 12, 20263d ago 144 Neutral 3/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
  4. Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
  5. Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $41.67 +20.39% settles Nov 17
  6. Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
  7. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
  8. Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
  9. Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
  10. Aug 25, 202611w ago 8-K Neutral 3/10 Entry $41.30 to $37.68 Now $41.67 +0.90% ▼ −8.77% −8.23% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 15, 2026